hotspot -WSS

hotspot

author：leisure time 2025-09-05 09:13:30 - browse：32

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Chemotherapy drug shortage eases slightly but still widespread

hotspot

WSS

Bill would stop addiction treatment from triggering child abuse inquiry

Why age limits for politicians are a terrible idea

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Why Charlie Gard's case is so disturbing to Americans

When women are denied an abortion, their children fare worse than peers

U.K. decision on ALS drug has neurologists, advocates up in arms

explore

hotspot

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Oral obesity drug from Viking Therapeutics hits key early target

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA rejects Alnylam's heart disease treatment over insufficient data

Medical records are filled with copy

Analysis of telehealth claims data suggest service duplication

Supreme Court strikes down use of affirmative action

Trial using CRISPR to edit HIV out of cells disappoints

Novavax promises a turnaround & Lilly roils the obesity market

FDA panel signals lack of confidence in Amgen cancer drug data

hotspot

Pancreatic cancer is often deadly, but new discoveries are raising hope

U.K. decision on ALS drug has neurologists, advocates up in arms

Why Charlie Gard's case is so disturbing to Americans

Senate panel eyes new effort on drug shortages

Young boy dies in trial for Pfizer Duchenne gene therapy

Overprescribed: High cost isn't America's only drug problem

hotspot

knowledge

focus

knowledge